BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hartmann J, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, Bokemeyer C. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer: . Anti-Cancer Drugs 1998;9:427-31. [DOI: 10.1097/00001813-199806000-00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Hartmann JT, Pintoffl JP, Al-batran S, Quietzsch D, Meisinger I, Horger M, Nehls O, Bokemeyer C, Königsrainer A, Jäger E, Kanz L. Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study. Oncol Res Treat 2007;30:235-40. [DOI: 10.1159/000100828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
2 Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-514. [PMID: 16091760 DOI: 10.1038/sj.bjc.6602733] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
3 Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT. Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives. Onkologie 2008;31:271-81. [PMID: 18497518 DOI: 10.1159/000122590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
4 Pugliano L, de Azambuja E. Treatment options in anthracycline and/or taxane pretreated patients with metastatic breast cancer. Onkologie 2012;35:476-8. [PMID: 23007143 DOI: 10.1159/000342209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Müller H, Nakchbandi W, Chatzissavvidis I, Valek V. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol 2001;27:652-61. [PMID: 11669594 DOI: 10.1053/ejso.2001.1193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
6 Propper DJ, Levitt NC, O'Byrne K, Braybrooke JP, Talbot DC, Ganesan TS, Thompson CH, Rajagopalan B, Littlewood TJ, Dixon RM, Harris AL. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer 2000;82:1776-82. [PMID: 10839290 DOI: 10.1054/bjoc.2000.1138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Hartmann J T, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L. Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer. 2003;89:2051-2056. [PMID: 14647137 DOI: 10.1038/sj.bjc.6601412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
8 Çubukçu A, Alponat A, Gönüllü NN, Özkan S, Erçin C. An Experimental Study Evaluating the Effect of Mitomycin C on the Prevention of Postoperative Intraabdominal Adhesions. Journal of Surgical Research 2001;96:163-6. [DOI: 10.1006/jsre.2000.6059] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
9 Deng YC, Zhen YS, Zheng S, Xue YC. Activity of boanmycin against colorectal cancer. World J Gastroenterol 2001; 7(1): 93-97 [PMID: 11819740 DOI: 10.3748/wjg.v7.i1.93] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bradner W. Mitomycin C: a clinical update. Cancer Treatment Reviews 2001;27:35-50. [DOI: 10.1053/ctrv.2000.0202] [Cited by in Crossref: 206] [Cited by in F6Publishing: 172] [Article Influence: 10.3] [Reference Citation Analysis]
11 Christiansen H, Hermann RM, Hille A, Schmidberger H, Martin² A, Nitsche M, Hess CF, Pradier O. Phase I study of continuous mitomycin-C infusion in concomitant radiochemotherapy of primary inoperable advanced head and neck cancer. J Cancer Res Clin Oncol 2005;131:815-20. [DOI: 10.1007/s00432-005-0028-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke H, Pflüger K, Batran SA, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anti-Cancer Drugs 2004;15:473-7. [DOI: 10.1097/01.cad.0000127144.73043.57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]